Home › Therapeutic areas › Immunology › Crohn's Disease
Crohn's Disease (6 companies)
Companies with an active program in Crohn's Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABVX | Abivax | Immunology | 1 | Phase 3 | $7.50B | 2 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $376M | 4 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | $197M | 3 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 1 | Approved | $8.62B | 12 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 3 | Phase 2 | $9.86B | 10 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.68B | 28 |
No companies match.